Pittenger & Anderson Inc. Reduces Position in Eli Lilly and Company (NYSE:LLY)

Pittenger & Anderson Inc. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 16.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 423 shares of the company’s stock after selling 82 shares during the period. Pittenger & Anderson Inc.’s holdings in Eli Lilly and Company were worth $247,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. Simon Quick Advisors LLC raised its stake in Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after buying an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC purchased a new position in Eli Lilly and Company in the fourth quarter worth $363,000. Hartline Investment Corp grew its holdings in Eli Lilly and Company by 1.1% in the fourth quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after purchasing an additional 248 shares during the last quarter. WASHINGTON TRUST Co grew its holdings in shares of Eli Lilly and Company by 16.5% during the fourth quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after buying an additional 2,671 shares during the last quarter. Finally, Liontrust Investment Partners LLP purchased a new stake in shares of Eli Lilly and Company during the third quarter valued at $8,326,000. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Barclays upped their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Morgan Stanley increased their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Citigroup increased their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Down 1.0 %

Shares of LLY traded down $7.33 during midday trading on Thursday, reaching $724.87. The stock had a trading volume of 2,599,682 shares, compared to its average volume of 3,033,906. Eli Lilly and Company has a 1-year low of $370.68 and a 1-year high of $800.78. The company’s fifty day simple moving average is $763.40 and its two-hundred day simple moving average is $664.52. The company has a market cap of $688.74 billion, a price-to-earnings ratio of 124.61, a PEG ratio of 1.63 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the business earned $2.09 EPS. The company’s revenue was up 28.1% on a year-over-year basis. Equities research analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.